A First in Human Study To Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors (BETA-PRIME)

This is the first clinical trial of AdAPT-001 for the treatment of cancer. AdAPT-001 is an oncolytic virus that is injected directly into the tumor. The purpose of this study is to find out the highest dose of AdAPT-001 that is safe and tolerable. This is the first step in studying whether it can be used to treat others with cancer in the future.

Inclusions/Exclusions: ECOG 0-2. No HIV allowed.

Learn More